Retroisosteric dipeptides, their preparation and use as renin inhibitors in pharmaceutical compositions.
Abstract
The invention relates to retroisosteric dipeptides of the general formula I <IMAGE> in which X, Q, A, B, D, L, M, Y, R1 and R2 have the meaning indicated in the description, to processes for their preparation and to their use as renin inhibitors in pharmaceutical compositions, especially in pharmaceutical compositions influencing the circulation.

Term
Term ended
Projected expiry passed 25 January 2011, 15.7 years ago.
- Priority
- Filed
- Published
- Projected expiry
- Today
10 claims: 4 independent, 6 dependent
- 1Retroisostere acylierte Dipeptide der allgemeinen Formel (I) in welcher X - für Indolyl, tert.-Butoxy, Morpholino oder für eine Gruppe der Formel oder für T steht, worin R 3 und R 3 ' gleich oder verschieden sind und geradkettiges oder verzweigtes Alkyl mit bis zu 8 Kohlenstoffatomen bedeuten, das gegebenenfalls durch Aryl mit 6 bis 10 Kohlenstoffatomen substituiert ist, n - eine Zahl 1, 2, 3 oder 4 bedeutet, W - eine Gruppe der Formel R 7 -CO-, R 8 -SO 2 - oder bedeutet, worin R 7 und R 8 gleich oder verschieden sind und geradkettiges oder verzweigtes Alkyl mit bis zu 8 Kohlenstoffatomen oder einen 6-gliedrigen Heterocyclus mit bis zu 3 Heteroatomen aus der Reihe Stickstoff, Sauerstoff oder Schwefel bedeuten, R 9 und R 9 ' gleich oder verschieden sind und Hydroxy oder Alkoxy mit bis zu 8 Kohlenstoffatomen bedeuten, R 4 - einen Kohlenhydratrest mit 4 bis 8 Kohlenstoffatomen bedeutet, wobei die OH-Funktionen des Zuckers gegebenenfalls geschützt sind, Q - Sauerstoff oder Schwefel bedeutet, R 5 und R G gleich oder verschieden sind und Wasserstoff, geradkettiges oder verzweigtes Alkyl mit bis zu 8 Kohlenstoffatomen, Phenyl oder eine Aminoschutzgruppe bedeuten, T - geradkettiges oder verzweigtes Alkenyl mit bis zu 8 Kohlenstoffatomen bedeutet, das gegebenenfalls durch Aryl mit 6 bis 10 Kohlenstoffatomen substituiert ist, das seinerseits durch Halogen, Hydroxy oder Alkoxy mit bis zu 6 Kohlenstoffatomen substituiert sein kann, A, B und D gleich oder verschieden sind und - für eine direkte Bindung oder - für einen Rest der Formel stehen worin m - die Zahl 1 oder 2 bedeutet, oder - für eine Gruppe der Formel stehen worin p - die Zahl 0 oder 1 bedeutet, R 10 Wasserstoff, geradkettiges oder verzweigtes Alkyl mit bis zu 6 Kohlenstoffatomen oder eine Aminoschutzgruppe bedeutet, R 11 und R 12 gleich oder verschieden sind und - Wasserstoff oder Cycloalkyl mit 3 bis 8 Kohlenstoffatomen bedeuten, oder - einen 3- bis 8-gliedrigen Heterocyclus mit bis zu 4 Heteroatomen aus der Reihe Stickstoff, Sauerstoff oder Schwefel bedeuten, - geradkettiges oder verzweigtes Alkyl mit bis zu 8 Kohlenstoffatomen bedeuten, das gegebenenfalls durch Alkylthio mit bis zu 6 Kohlenstoffatomen, Hydroxy, Mercapto, Guanidyl oder durch eine Gruppe der Formel -NR 5 R 6 oder R 13 -OC- substituiert ist, worin R 5 und R 6 die oben angegebene Bedeutung haben und R 13 Hydroxy, Benzyloxy, Alkoxy mit bis zu 6 Kohlenstoffatomen oder die oben aufgeführte Gruppe -NR 5 R 6 bedeutet, oder das gegebenenfalls durch Aryl mit 6 bis 10 Kohlenstoffatomen substituiert ist, das seinerseits durch Hydroxy, Halogen, Nitro, Alkoxy mit bis zu 8 Kohlenstoffatomen oder durch die Gruppe -NR 5 R 6 substituiert sein kann, worin R 5 und R G die oben angegebene Bedeutung haben oder das gegebenenfalls durch einen 5-oder 6-gliedrigen stickstoffhaltigen Heterocyclus oder Indolyl substituiert ist, worin die entsprechenden -NH-Funktionen gegebenenfalls durch Alkyl mit bis zu 6 Kohlenstoffatomen oder durch eine Aminoschutzgruppe geschützt sind, L und M gleich oder verschieden sind und - für eine direkte Bindung oder - für eine Gruppe der Formel stehen worin p' , R 10' , R 11' und R' 2 ' die oben angegebene Bedeutung von p, R 10 , R 11 und R 12 haben, in ihrer D- oder L-Form oder als D,L-Isomerengemisch, R 1 und R 2 gleich oder verschieden sind und - für geradkettiges oder verzweigtes Alkyl mit bis zu 8 Kohlenstoffatomen stehen, das gegebenenfalls durch Cycloalkyl mit 3 bis 8 Kohlenstoffatomen oder Aryl mit 6 bis 10 Kohlenstoffatomen substituiert ist, Y - für eine Gruppe der Formel oder -CO-R 14 steht, worin Q und R 4 die oben angegebene Bedeutung haben, R 14 geradkettiges oder verzweigtes Alkyl mit bis zu 8 Kohlenstoffatomen bedeutet, das gegebenenfalls durch Pyridyl, Phenyl oder die Gruppe -NR 15 R 16 substituiert ist, worin R 15 und R 16 entweder die oben angegebene Bedeutung von R 5 und R G haben und mit dieser gleich oder verschieden sind oder R 15 Wasserstoff bedeutet und R 16 die Gruppe der Formel oder bedeutet worin W, Q, n, R 3 und R 4 die oben angegebene Bedeutung haben und deren physiologisch unbedenklichen Salze, mit der Maßgabe, daß X nur dann tert.-Butoxy bedeuten darf, wenn Y für die Gruppe Q oder steht.
- 2Verbindungen der allgemeinen Formel (I) gemäß Anspruch 1, in welcher X - für Indolyl, tert.-Butoxy, Morpholino oder für eine Gruppe der Formel oder für T steht, worin R 3 und R 3 ' gleich oder verschieden sind und geradkettiges oder verzweigtes Alkyl mit bis zu 6 Kohlenstoffatomen bedeuten, das gegebenenfalls durch Phenyl oder Naphthyl substituiert ist, n - eine Zahl 1, 2 oder 3 bedeutet, W - eine Gruppe der Formel R 7- C0-, R S- S0 2 - oder bedeutet worin R 7 und R 8 gleich oder verschieden sind und geradkettiges oder verzweigtes Alkyl mit bis zu 6 Kohlenstoffatomen oder Morpholino bedeuten, R 9 und R 9' gleich oder verschieden sind und Hydroxy oder Alkoxy mit bis zu 6 Kohlenstoffatomen bedeuten, R 4 einen Pyranosylrest bedeutet, wobei die OH-Funktionen des Zuckers gegebenenfalls geschützt wird, Q - Sauerstoff oder Schwefel bedeutet, R 5 und R 6 gleich oder verschieden sind und Wasserstoff, geradkettiges oder verzweigtes Alkyl mit bis zu 6 Kohlenstoffatomen oder eine Aminoschutzgruppe bedeuten, T - geradkettiges oder verzweigtes Alkyl oder Alkenyl mit bis zu 6 Kohlenstoffatomen bedeutet, das gegebenenfalls durch Phenyl substituiert ist, das seinerseits durch Fluor, Chlor, Hydroxy oder Alkoxy mit bis zu 4 Kohlenstoffatomen substituiert ist, A, B und D gleich oder verschieden sind und - für eine direkte Bindung oder - für Prolin stehen, oder - für eine Gruppe der Formel stehen worin R 10 Wasserstoff oder geradkettiges oder verzweigtes Alkyl mit bis zu 4 Kohlenstoffatomen bedeutet, R" und R 12 gleich oder verschieden sind und Cyclopentyl, Cyclohexyl, Wasserstoff oder geradkettiges oder verzweigtes Alkyl mit bis zu 6 Kohlenstoffatomen bedeuten, das gegebenenfalls durch Naphthyl oder Phenyl substituiert ist, die ihrerseits durch Fluor, Chlor, Nitro oder Alkoxy mit bis zu 6 Kohlenstoffatomen substituiert sein können, oder durch Indolyl, Imidazolyl, Pyridyl, Triazolyl oder Pyrazolyl substituiert ist, wobei die entsprechenden -NH-Funktionen gegebenenfalls durch Alkyl mit bis zu 4 Kohlenstoffatomen oder durch eine Aminoschutzgruppe substituiert sind, L und M gleich oder verschieden sind und - für eine direkte Bindung oder - für eine Gruppe der Formel stehen worin R 10' , R 11' und R 12' die oben angegebene Bedeutung von R 10 , R 11 und R 12 haben und mit dieser gleich oder verschieden sind, in ihrer D- oder L-Form, oder als D,L-Isomerengemisch, R 1 und R 2 gleich oder verschieden sind und für geradkettiges oder verzweigtes Alkyl mit bis zu 6 Kohlenstoffatomen stehen, das gegebenenfalls durch Cyclopropyl, Cyclopentyl, Cyclohexyl oder Phenyl substituiert ist, Y - für eine Gruppe der Formel oder -CO-R14 steht, worin Q und R 4 die oben angegebene Bedeutung haben, R 14 geradkettiges oder verzweigtes Alkyl mit bis zu 6 Kohlenstoffatomen bedeutet, das gegebenenfalls durch Pyridyl, Phenyl oder durch die Gruppe -NR 15 R 16 substituiert ist, worin R 15 und R 16 entweder gleich oder verschieden sind und die oben angegebene Bedeutung von R 5 und R 6 haben und mit dieser gleich oder verschieden sind, oder R 15 Wasserstoff bedeutet und R 16 für eine Gruppe der Formel oder steht, W, Q, n, R 3 und R 4 die oben angegebene Bedeutung haben und deren physiologisch unbedenklichen Salze, mit der Maßgabe, daß X nur dann tert.-Butoxy bedeuten darf, wenn Y für die Gruppe Q oder steht.
- 3Verbindungen der allgemeinen Formel (I) gemäß Anspruch 1, in welcher X - für Indolyl, tert.-Butoxy, Morpholino oder für eine Gruppe der Formel oder für T steht, worin R 3 und R 3 ' gleich oder verschieden sind und geradkettiges oder verzweigtes Alkyl mit bis zu 4 Kohlenstoffatomen bedeuten, das gegebenenfalls durch Phenyl oder Naphthyl substituiert ist, n - eine Zahl 1 oder 2 bedeutet, W - eine Gruppe der Formel bedeutet, worin R 7 und R 8 gleich oder verschieden sind und geradkettiges oder verzweigtes Alkyl mit bis zu 4 Kohlenstoffatomen oder Morpholino bedeuten, R 9 und R 9 ' gleich oder verschieden sind und Hydroxy oder Alkoxy mit bis zu 4 Kohlenstoffatomen bedeuten, R 4 - einen Rest der Formel bedeutet worin die OH-Funktionen gegebenenfalls durch Acetyl geschützt sind Q - Sauerstoff oder Schwefel bedeutet, R 5 und R 6 gleich oder verschieden sind und Wasserstoff, geradkettiges oder verzweigtes Alkyl mit bis zu 4 Kohlenstoffatomen oder eine Aminoschutzgruppe bedeuten, T - den Rest der Formel bedeutet, A, B und D gleich oder verschieden sind und - für eine direkte Bindung oder - für Prolin stehen, oder - für eine Gruppe der Formel stehen, worin R 10 Wasserstoff oder Methyl bedeutet, R 11 und R 12 gleich oder verschieden sind und Wasserstoff, Cyclopentyl oder geradkettiges oder verzweigtes Alkyl mit bis zu 4 Kohlenstoffatomen bedeuten, das gegebenenfalls durch Naphthyl oder Phenyl substituiert ist, die ihrerseits durch Fluor, Chlor oder Alkoxy mit bis zu 4 Kohlenstoffatomen substituiert sein können, oder Alkyl durch Imidazolyl, Triazolyl, Pyridyl oder Pyrazolyl substituiert ist, wobei die -NH-Funktionen gegebenenfalls durch Methyl, Boc oder BOM geschützt sind, L und M gleich oder verschieden sind und - für eine direkte Bindung oder - für eine Gruppe der Formel stehen, worin R 10' , R 11' und R 12 ' die oben angegebene Bedeutung von R 10 , R 11 und R 12 haben und mit dieser gleich oder verschieden sind, in ihrer D- oder L-Form, oder als D,L-Isomerengemisch, R' und R 2 gleich oder verschieden sind und - für geradkettiges oder verzweigtes Alkyl mit bis zu 4 Kohlenstoffatomen stehen, das gegebenenfalls durch Cyclohexyl oder Phenyl substituiert ist, Y - für eine Gruppe der Formel oder -CO-R 14 steht, worin Q und R 4 die oben angegebene Bedeutung haben, R 14 geradkettiges oder verzweigtes Alkyl mit bis zu 4 Kohlenstoffatomen bedeutet, das gegebenenfalls durch Pyridyl, Phenyl oder durch die Gruppe -NR 15 R 16 substituiert ist, worin R 15 Wasserstoff bedeutet und R 16 eine Gruppe der Formel oder bedeutet, worin W, Q, n, R 3 und R 4 die oben angegebene Bedeutung haben und deren physiologisch unbedenklichen Salze, mit der Maßgabe, daß X nur dann tert.-Butoxy bedeuten darf, wenn Y für die Gruppe Q oder steht.
- 4Verbindungen der allgemeinen Formel (I) gemäß Anspruch 1, zur Verwendung bei der Bekämpfung von Krankheiten.
- 5Verfahren zur Herstellung von retroisosteren Dipeptiden der allgemeinen Formel (I) in welcher X - für Indolyl, tert.-Butoxy, Morpholino oder für eine Gruppe der Formel oder für T steht, worin R 3 und R 3 ' gleich oder verschieden sind und geradkettiges oder verzweigtes Alkyl mit bis zu 8 Kohlenstoffatomen bedeuten, das gegebenenfalls durch Aryl mit 6 bis 10 Kohlenstoffatomen substituiert ist, n - eine Zahl 1, 2, 3 oder 4 bedeutet, W - eine Gruppe der Formel R 7 -CO-, R 8- S0 2 - oder bedeutet, worin R 7 und R 9 gleich oder verschieden sind und geradkettiges oder verzweigtes Alkyl mit bis zu 8 Kohlenstoffatomen oder einen 6-gliedrigen Heterocyclus mit bis zu 3 Heteroatomen aus der Reihe Stickstoff, Sauerstoff oder Schwefel bedeuten, R 9 und R 9 ' gleich oder verschieden sind und Hydroxy oder Alkoxy mit bis zu 8 Kohlenstoffatomen bedeuten, R 4 - einen Kohlenhydratrest mit 4 bis 8 Kohlenstoffatomen bedeutet, wobei die OH-Funktionen des Zuckers gegebenenfalls geschützt sind, Q - Sauerstoff oder Schwefel bedeutet, R 5 und R G gleich oder verschieden sind und Wasserstoff, geradkettiges oder verzweigtes Alkyl mit bis zu 8 Kohlenstoffatomen, Phenyl oder eine Aminoschutzgruppe bedeuten, T - geradkettiges oder verzweigtes Alkenyl mit bis zu 8 Kohlenstoffatomen bedeutet, das gegebenenfalls durch Aryl mit 6 bis 10 Kohlenstoffatomen substituiert ist, das seinerseits durch Halogen, Hydroxy oder Alkoxy mit bis zu 6 Kohlenstoffatomen substituiert sein kann,m A, B und D gleich oder verschieden sind und - für eine direkte Bindung oder - für einen Rest der Formel stehen worin m - die Zahl 1 oder 2 bedeutet, oder - für eine Gruppe der Formel stehen worin p - die Zahl 0 oder 1 bedeutet, R 10 Wasserstoff, geradkettiges oder verzweigtes Alkyl mit bis zu 6 Kohlenstoffatomen oder eine Aminoschutzgruppe bedeutet, R 11 und R12 gleich oder verschieden sind und - Wasserstoff oder Cycloalkyl mit 3 bis 8 Kohlenstoffatomen bedeuten, oder - einen 3- bis 8-gliedrigen Heterocyclus mit bis zu 4 Heteroatomen aus der Reihe Stickstoff, Sauerstoff oder Schwefel bedeuten, - geradkettiges oder verzweigtes Alkyl mit bis zu 8 Kohlenstoffatomen bedeuten, das gegebenenfalls durch Alkylthio mit bis zu 6 Kohlenstoffatomen, Hydroxy, Mercapto, Guanidyl oder durch eine Gruppe der Formel -NR 5 R 6 oder R 13 -OC- substituiert ist, worin R 5 und R 6 die oben angegebene Bedeutung haben und R 13 Hydroxy, Benzyloxy, Alkoxy mit bis zu 6 Kohlenstoffatomen oder die oben aufgeführte Gruppe -NR 5 R 6 bedeutet, oder das gegebenenfalls durch Aryl mit 6 bis 10 Kohlenstoffatomen substituiert ist, das seinerseits durch Hydroxy, Halogen, Nitro, Alkoxy mit bis zu 8 Kohlenstoffatomen oder durch die Gruppe -NR 5 R 6 substituiert sein kann, worin R 5 und R 6 die oben angegebene Bedeutung haben oder das gegebenenfalls durch einen 5- oder 6-gliedrigen stickstoffhaltigen Heterocyclus oder Indolyl substituiert ist, worin die entsprechenden -NH-Funktionen gegebenenfalls durch Alkyl mit bis zu 6 Kohlenstoffatomen oder durch eine Aminoschutzgruppe geschützt sind, L und M gleich oder verschieden sind und - für eine direkte Bindung oder - für eine Gruppe der Formel stehen worin p' , R 10' , R 11' und R 12' die oben angegebene Bedeutung von p, R 10 , R" und R 12 haben, in ihrer D- oder L-Form oder als D,L-Isomerengemisch, R 1 und R 2 gleich oder verschieden sind und - für geradkettiges oder verzweigtes Alkyl mit bis zu 8 Kohlenstoffatomen stehen, das gegebenenfalls durch Cycloalkyl mit 3 bis 8 Kohlenstoffatomen oder Aryl mit 6 bis 10 Kohlenstoffatomen substituiert ist, Y - für eine Gruppe der Formel oder -CO-R 14 steht, worin Q und R 4 die oben angegebene Bedeutung haben, R 14 geradkettiges oder verzweigtes Alkyl mit bis zu 8 Kohlenstoffatomen bedeutet, das gegebenenfalls durch Pyridyl, Phenyl oder die Gruppe -NR 15 R 16 substituiert ist, worin R 15 und R 16 entweder die oben angegebene Bedeutung von R 5 und R 6 haben und mit dieser gleich oder verschieden sind oder R 15 Wasserstoff bedeutet und R 16 die Gruppe der Formel oder bedeutet worin W, Q, n, R 3 und R 4 die oben angegebene Bedeutung haben, mit der Maßgabe, daß X nur dann tert.-Butoxy bedeuten darf, wenn Y für die Gruppe oder steht, dadurch gekennzeichnet, daß man Verbindungen der allgemeinen Formel (II) in welcher R 1 und R 2 die oben angegebene Bedeutung haben, G - für eine der oben aufgeführten Aminoschutzgruppen steht, und V - für einen hydrogenolytisch abspaltbaren Rest, wie beispielsweise Benzyl steht, zunächst durch Hydrogenolyse unter Öffnung des Isoxazolidinrings zu den Aminoalkoholen der allgemeinen Formel (III) worin G, Z, R 1 und R 2 die oben angegebene Bedeutung haben, reduziert, gegebenenfalls anschließend mit Verbindungen der allgemeinen Formel (IV) oder (IVa) in welcher Y die oben angegebene Bedeutung hat und L' und M' die oben angegebene Bedeutung von L und M haben, aber nicht gleichzeitig für eine direkte Bindung stehen, in inerten Lösemitteln, gegebenenfalls in Anwesenheit eines wasserentziehenden Hilfsstoffes und/oder einer Base kondensiert, anschließend nach Abspaltung der Schutzgruppe G nach bekannter Methode mit Verbindungen der allgemeinen Formel (V) in welcher B' und D' die oben angegebene Bedeutung von B und D haben, aber nicht gleichzeitig für eine direkte Bindung stehen und G die oben angegebene Bedeutung von G hat und mit dieser gleich oder verschieden ist, umsetzt und in einem letzten Schritt nach Abspaltung der Schutzgruppe G' mit Verbindungen der Formel (VI) in welcher X und Q die oben angegebene Bedeutung haben und A' die oben angegebene Bedeutung von A hat, aber nicht für eine direkte Bindung steht, gegebenenfalls in Anwesenheit einer Base umsetzt.
- 6Verbindungen der allgemeinen Formel (II) in welcher R 1 und R 2 gleich oder verschieden sind und für geradkettiges oder verzweigtes Alkyl mit bis zu 8 Kohlenstoffatomen stehen, das gegebenenfalls durch Cycloalkyl mit 3 bis 8 Kohlenstoffatomen oder durch Aryl mit 6 bis 10 Kohlenstoffatomen substituiert ist, G für eine Aminoschutzgruppe steht und V für einen hydrogenolytisch abspaltbaren Rest wie z.B. Benzyl steht.
- 7Verfahren zur Herstellung von Verbindungen der allgemeinen Formel (II) in welcher R 1 und R 2 die oben angegebene Bedeutung haben, G - für eine der oben aufgeführten Aminoschutzgruppen steht, und V - für einen hydrogenolytisch abspaltbaren Rest, wie beispielsweise Benzyl steht, dadurch gekennzeichnet, daß man Verbindungen der allgemeinen Formel (VII) in welcher G die oben angegebene Bedeutung hat, in einer Cycloadditionsreaktion mit Verbindungen der allgemeinen Formel (VIII) in welcher V und R 2 die oben angegebene Bedeutung haben, gegebenenfalls in Gegenwart von inerten organischen Lösungsmitteln umsetzt.
- 8Arzneimittel, enthaltend mindestens eine Verbindung der allgemeinen Formel (I) gemäß Anspruch 1.
- 9Verfahren zur Herstellung von Arzneimitteln, dadurch gekennzeichnet, daß man mindestens eine Verbindung der allgemeinen Formel (1) gemäß Anspruch 1 gegebenenfalls unter Verwendung üblicher Hilfs- und Trägerstoffe in eine geeignete Applikationsform überführt.
- 10Verwendung von Verbindungen der allgemeinen Formel (I) gemäß Anspruch 1 bei der Herstellung von Arzneimitteln mit renininhibitorischer Wirkung.
Independent claims10
139 paragraphs, as filed
0001The invention relates to new retroisosteric dipeptides, processes for their preparation and their use as renin inhibitors in medicaments, in particular in medicaments which influence the circulation.
0002Renin is a proteolytic enzyme that is mainly produced by the kidneys and secreted into the plasma. It is known that renin cleaves the decapeptide angiotensin I from the angiotensinogen in vivo. Angiotensin 1 in turn is broken down in the lungs, kidneys or other tissues to form the blood pressure-effective octapeptide angiotensin 11. The various effects of angiotensin 11 such as vasoconstriction, Na retention in the kidney, aldosterone release in the adrenal gland and increased tone of the sympathetic nervous system act synergistically in the sense of an increase in blood pressure.
0003The activity of the renin-angiotensin system can be pharmacologically manipulated by inhibiting the activity of renin or the angiotensin conversion enzyme (ACE) and by blocking angiotensin II receptors. The development of ACE inhibitors which can be used orally has thus led to new antihypertensives (cf. DOS 3 628 650, Am. J. Med. 77, 690, 1984). However, ACE also acts on substrates other than angiotensin such as kinins. These can cause undesirable side effects such as prostaglandin release and a number of behavioral and neurological effects. ACE inhibition also causes angiotensin I to accumulate.
0004A specific approach is to intervene in the renin-angiotensin cascade at an earlier point in time, namely by inhibiting the acidic aspartase renin, which only recognizes angiotensinogen as a substrate.
0005So far, different types of renin inhibitors have been developed: renin-specific antibodies, phospholipids, peptides with the N-terminal sequence of prorenin, synthetic peptides as substrate analogues and modified peptides. In many renin inhibitors, the Leu-Val dipeptide is also replaced by statin (EP 077 029) or by isosteric dipeptides (cf. US 442 42 07).
0006In addition, PCT WO 88/02374 includes renin inhibitors which contain retroisosteric dipeptide units as the protease-stable central central part. Retroisosteric dipeptides have a head-end amino group; the coupling to C-terminal amino acids leads to a reversal of the amide function (retroamide), which is characterized by a high metabolic stability towards enzymatic degradation.
0007Using the process according to the invention, new renin inhibitors were found which surprisingly have a high selectivity towards human renin and good oral effectiveness.
0008The invention relates to retroisosteric acylated dipeptides of the general formula (I)<chemistry id="chem0001" num="0001"><img file="EP0441192A2_D0001.tif" /></chemistry>in which<ul id="ul0001" list-style="none"><li>X - for indolyl, tert-butoxy, morpholino or for a group of the formula<chemistry id="chem0002" num="0002"><img file="EP0441192A2_D0002.tif" /></chemistry>or T, where<ul id="ul0002" list-style="none"><li>R<sup>3</sup> and R<sup>3</sup>are identical or different and represent straight-chain or branched alkyl having up to 8 carbon atoms, which is optionally substituted by aryl having 6 to 10 carbon atoms,</li><li>n - is a number 1, 2, 3 or 4,</li><li>W - a group of the formula</li><li>R<sup>7-</sup>Co-, R<sup>8-</sup>S0<sub>2</sub>- or<chemistry id="chem0003" num="0003"><img file="EP0441192A2_D0003.tif" /></chemistry>means</li><li>wherein</li><li>R<sup>7</sup> and R<sup>8</sup> are identical or different and represent straight-chain or branched alkyl having up to 8 carbon atoms or a 6-membered heterocycle having up to 3 heteroatoms from the series nitrogen, oxygen or sulfur,</li><li>R<sup>9</sup> and R<sup>9</sup>are the same or different and denote hydroxy or alkoxy having up to 8 carbon atoms,</li><li>R<sup>4 -</sup> is a carbohydrate residue with 4 to 8 carbon atoms, the OH functions of the sugar being protected where appropriate,</li><li>Q - means oxygen or sulfur,</li><li>R<sup>5</sup> and R<sup>6</sup> are identical or different and are hydrogen, straight-chain or branched alkyl having up to 8 carbon atoms, phenyl or an amino protecting group,</li><li>T denotes straight-chain or branched alkenyl having up to 8 carbon atoms, which is optionally substituted by aryl having 6 to 10 carbon atoms, which in turn can be substituted by halogen, hydroxyl or alkoxy having up to 6 carbon atoms,</li></ul></li><li>A, B and D are the same or different and<ul id="ul0003" list-style="none"><li>- for a direct bond or</li><li>- for a remainder of the formula<chemistry id="chem0004" num="0004"><img file="EP0441192A2_D0004.tif" /></chemistry>stand</li><li>wherein</li><li>m - the number 1 or 2 means</li><li>or</li><li>- for a group of the formula<chemistry id="chem0005" num="0005"><img file="EP0441192A2_D0005.tif" /></chemistry>stand</li><li>wherein</li><li>p - the number 0 or 1,</li><li>R<sup>10</sup> Represents hydrogen, straight-chain or branched alkyl having up to 6 carbon atoms or an amino protecting group,</li><li>R<sup>11</sup> and R<sup>12</sup> are the same or different and<ul id="ul0004" list-style="none"><li>Mean hydrogen or cycloalkyl having 3 to 8 carbon atoms, or</li><li>a 3- to 8-membered heterocycle with up to 4 heteroatoms from the series nitrogen, oxygen or sulfur,</li><li>straight-chain or branched alkyl having up to 8 carbon atoms, optionally by alkylthio having up to 6 carbon atoms, hydroxyl, mercapto, guanidyl or by a group of the formula -NR<sup>5</sup>R<sup>6</sup> or R<sup>13</sup>-OC- is substituted, wherein</li></ul></li><li>R<sup>5</sup> and R<sup>6</sup> have the meaning given above</li><li>and</li><li>R<sup>13</sup> Hydroxy, benzyloxy, alkoxy with up to 6 carbon atoms or the group listed above</li><li>-NO<sup>5</sup>R<sup>6</sup> means, or which is optionally substituted by aryl having 6 to 10 carbon atoms, which in turn by hydroxy, halogen, nitro, alkoxy having up to 8 carbon atoms or by the group -NR<sup>5</sup>R<sup>6</sup> can be substituted</li><li>wherein</li><li>R<sup>5</sup> and R<sup>6</sup> have the meaning given above or which is optionally substituted by a 5- or 6-membered nitrogen-containing heterocycle or indolyl, in which the corresponding -NH functions are optionally protected by alkyl having up to 6 carbon atoms or by an amino protecting group,</li></ul></li><li>L and M are the same or different and</li><li>- for a direct bond or</li><li>- for a group of the formula<chemistry id="chem0006" num="0006"><img file="EP0441192A2_D0006.tif" /></chemistry>stand</li><li>wherein</li><li>p ', R<sup>10'</sup>, R<sup>11'</sup> and R<sup>12'</sup> the meaning of p, R given above<sup>10</sup>, R<sup>11</sup> and R<sup>12</sup> to have,</li><li>in their D or L form or as a D, L isomer mixture,</li><li>R<sup>1</sup> and R<sup>2</sup> are the same or different and</li><li>stand for straight-chain or branched alkyl having up to 8 carbon atoms, which is optionally substituted by cycloalkyl having 3 to 8 carbon atoms or aryl having 6 to 10 carbon atoms, Y is a group of the formula<chemistry id="chem0007" num="0007"><img file="EP0441192A2_D0007.tif" /></chemistry>or -CO-R<sup>14</sup> stands,</li><li>wherein</li><li>Q and R<sup>4</sup> have the meaning given above,</li><li>R<sup>14</sup> straight-chain or branched alkyl having up to 8 carbon atoms, optionally by pyridyl, phenyl or the group -NR<sup>15</sup>R<sup>16</sup> is substituted,</li><li>where R<sup>15</sup> and R<sup>16</sup> either the meaning of R given above<sup>5</sup> and R<sup>6</sup> have and are the same or different with it or R<sup>15</sup> Is hydrogen and R<sup>16</sup> the group of the formula<chemistry id="chem0008" num="0008"><img file="EP0441192A2_D0008.tif" /></chemistry>means what</li><li>W, Q, n, R<sup>3</sup> and R<sup>4</sup> have the meaning given above and their physiologically acceptable salts, with the proviso that X may only mean tert-butoxy if Y is for the group<chemistry id="chem0009" num="0009"><img file="EP0441192A2_D0009.tif" /></chemistry>stands.</li></ul>
0009The usual protective groups such as methylbenzoyl, benzoyl, acetyl or benzyl are suitable as OH protective groups. Benzyl or acetyl are preferred. Acetyl (Ac) is particularly preferred.
0010Within the scope of the invention, amino protecting groups stand for the usual amino protecting groups used in peptide chemistry.
0011These preferably include; Benzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 2-chlorobenzyloxycarbonyl, 3-chlorobenzyloxycarbonyl, 3,5-dimethoxybenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 2-nitrobenzyloxycarbonyl, 2-nitro-4,5-dimethoxybenzyloxycarbonyl Ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, tert-butoxycarbonyl, pentoxycarbonyl, isopentoxycarbonyl, cyclohexoxycarbonyl, 2-chloroethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2,2,2-trichloro-tert-butoxycarbonyl, benzhydryloxycarbonyl, bis- (4-methoxyphenyl) methoxycarbonyl, phenacyloxycarbonyl, 2-trimethylsilylethoxycarbonyl, 2-triphenylsilylethoxycarbonyl, menthyloxycarbonyl, vinyloxycarbonyl, allyloxycarbonyl, fluorenyl-9-methoxycarbonyl, ethoxycarbonyl, 9-methoxycarbonyl, ethoxycarbonyl, 9-methoxycarbonyl , Tert-butylthiocarbonyl, benzylthiocarbonyl, formyl, acetyl, propionyl, pivaloyl, 2-chloroacetyl, 2-bromoacetyl, 2-iodoacetyl, 2,2,2-trifluoroacetyl, 2,2,2-trichloroacetyl, Benzoyl, 4-chlorobenzoyl, 4-methoxybenzoyl, 4-nitrobenzyl, 4-nitrobenzoyl, naphthylcarbonyl, phenoxyacetyl, adamantylcarbonyl, dicyclohexylphosphoryl, diphenylphosphoryl, dibenzylphosphoryl, di- (4-nitrobenzylphenyl) phosphyll, or
0012Particularly preferred amino protecting groups are benzyloxycarbonyl, 3,5-dimethoxybenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 2-nitrobenzyloxycarbonyl, 3,4,5-trimethoxybenzyloxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, tert-butoxyethoxycarbonyl, cyclo-chlorooxycarbonyl, cyclo Naphthylcarbonyl, adamantylcarbonyl, phthaloyl, 2,2,2-trichloroethoxycarbonyl, 2,2,2-trichloro-tert-butoxycarbonyl, menthyloxycarbonyl, vinyloxycarbonyl, Allyloxycarbonyl, fluorenyl-9-methoxycarbonyl, formyl, acetyl, propionyl, pivaloyl, 2-chloroacetyl, 2-bromoacetyl, 2,2,2-trifluoroacetyl, 2,2,2-trichloroacetyl, benzoyl, 4-chlorobenzoyl, 4-bromobenzoyl, 4-nitrobenzoyl, isovaleroyl or benzyloxymethyl.
0013The compounds of the general formula (I) according to the invention have several asymmetric carbon atoms. They can exist independently of one another in the D or L form. The invention encompasses the optical antipodes as well as the isomer mixtures or racemates. The groups A, B, D, L and M are preferably present independently of one another in the optically pure, preferably in the L-form.
0014The group of the formula<chemistry id="chem0010" num="0010"><img file="EP0441192A2_D0010.tif" /></chemistry>has 3 asymmetric carbon atoms (1,3,4), which can exist independently of one another in the R or S configuration. This group is preferably in the 1 R, 3S, 4S configuration, 1R, 3R, 4S configuration, 1S, 3R, 4S configuration or in the 1S, 3S, 4S configuration.
0015The 1S, 3S, 4S configuration and the 1 R, 3S, 4S configuration which, depending on the nature of the substituent R, are particularly preferred<sup>2</sup> reflect the configuration of an L, L dipeptide.
0016The compounds of the general formula (I) according to the invention can be present in the form of their salts. These can be salts of the compounds according to the invention with inorganic or organic acids or bases. The acid addition products preferably include salts with hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid or with carboxylic acids such as acetic acid, propionic acid, oxalic acid, glycolic acid, succinic acid, maleic acid, hydroxymaleic acid, methylmaleic acid , Fumaric acid, adipic acid, malic acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, lactic acid, Ascorbic acid, salicylic acid, 2-acetoxybenzoic acid, nicotinic acid, isonicotinic acid, or sulfonic acids such as methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, toluenesulfonic acid, naphthalenesulfonic acids.
0017Compounds of the general formula (I) in which<ul id="ul0005" list-style="none"><li>X - for indolyl, terf-butoxy, morpholino or for a group of the formula<chemistry id="chem0011" num="0011"><img file="EP0441192A2_D0011.tif" /></chemistry>or T, where<ul id="ul0006" list-style="none"><li>R<sup>3</sup> and R<sup>3</sup>are identical or different and represent straight-chain or branched alkyl having up to 6 carbon atoms, which is optionally substituted by phenyl or naphthyl,</li><li>n - represents a number 1, 2 or 3,</li><li>W - a group of the formula</li><li>R<sup>7-</sup>C0-, R<sup>8-</sup>S0<sub>2</sub>- or<chemistry id="chem0012" num="0012"><img file="EP0441192A2_D0012.tif" /></chemistry>means what<ul id="ul0007" list-style="none"><li>R<sup>7</sup> and R<sup>8</sup> are identical or different and represent straight-chain or branched alkyl having up to 6 carbon atoms or morpholino,</li><li>R<sup>9</sup> and R<sup>9</sup>are the same or different and denote hydroxy or alkoxy having up to 6 carbon atoms,</li></ul></li><li>R<sup>4</sup> is a pyranosyl radical, the OH functions of the sugar optionally being protected,</li><li>Q - means oxygen or sulfur,</li><li>R<sup>5</sup> and R<sup>6</sup> are identical or different and denote hydrogen, straight-chain or branched alkyl having up to 6 carbon atoms or an amino protecting group,</li><li>T means straight-chain or branched alkenyl with up to 6 carbon atoms, which is optionally substituted by phenyl, which in turn is substituted by fluorine, chlorine, hydroxy or alkoxy with up to 4 carbon atoms,</li></ul></li><li>A, B and D are the same or different and</li><li>- for a direct bond or</li><li>- stand for proline, or</li><li>- for a group of the formula<chemistry id="chem0013" num="0013"><img file="EP0441192A2_D0013.tif" /></chemistry>stand</li><li>where R<sup>10</sup> Is hydrogen or straight-chain or branched alkyl having up to 4 carbon atoms, R<sup>11</sup> and R<sup>12</sup> are identical or different and mean cyclopentyl, cyclohexyl, hydrogen or straight-chain or branched alkyl having up to 6 carbon atoms, which is optionally substituted by naphthyl or phenyl, which in turn can be substituted by fluorine, chlorine, nitro or alkoxy having up to 6 carbon atoms, or is substituted by indolyl, imidazolyl, pyridyl, triazolyl or pyrazolyl, wherein the corresponding -NH functions are optionally substituted by alkyl having up to 4 carbon atoms or by an amino protecting group, L and M are the same or different and</li><li>- for a direct bond or</li><li>- for a group of the formula<chemistry id="chem0014" num="0014"><img file="EP0441192A2_D0014.tif" /></chemistry>stand in what</li><li>R<sup>10'</sup>, R<sup>11'</sup> and R<sup>12'</sup> the meaning of R given above<sup>10</sup>, R<sup>11</sup> and R<sup>12</sup> have and are the same or different with it,</li><li>in their D or L form, or as a D, L isomer mixture,</li><li>R<sup>1</sup> and R<sup>2</sup> are identical or different and stand for straight-chain or branched alkyl having up to 6 carbon atoms, which is optionally substituted by cyclopropyl, cyclopentyl, cyclohexyl or phenyl, Y - for a group of the formula<chemistry id="chem0015" num="0015"><img file="EP0441192A2_D0015.tif" /></chemistry>or -CO-R<sup>14</sup> stands,</li><li>where Q and R<sup>4</sup> have the meaning given above,</li><li>R<sup>14</sup> straight-chain or branched alkyl having up to 6 carbon atoms, optionally by pyridyl, phenyl or by the group -NR<sup>15</sup>R<sup>16</sup> is substituted,</li><li>wherein</li><li>R<sup>15</sup> and R<sup>16</sup> are either the same or different and have the meaning of R given above<sup>S</sup> and R<sup>6</sup> have and are the same or different with it, or</li><li>R<sup>15</sup> Means hydrogen and</li><li>R<sup>16</sup> for a group of the formula<chemistry id="chem0016" num="0016"><img file="EP0441192A2_D0016.tif" /></chemistry>or<chemistry id="chem0017" num="0017"><img file="EP0441192A2_D0017.tif" /></chemistry>stands in what</li><li>U, Q, n, R<sup>3</sup> and R<sup>4</sup> have the meaning given above and their physiologically acceptable salts, with the proviso that X may only mean tert-butoxy if Y is for the group<chemistry id="chem0018" num="0018"><img file="EP0441192A2_D0018.tif" /></chemistry>stands.</li></ul>
0018Compounds of the general formula (I) in which<ul id="ul0008" list-style="none"><li>X - for indolyl, tert-butoxy, morpholino or for a group of the formula<chemistry id="chem0019" num="0019"><img file="EP0441192A2_D0019.tif" /></chemistry>R<sup>4-</sup>NH-,<chemistry id="chem0020" num="0020"><img file="EP0441192A2_D0020.tif" /></chemistry>or represents T, where R<sup>3</sup> and R<sup>3</sup>'are identical or different and represent straight-chain or branched alkyl having up to 4 carbon atoms, which is optionally substituted by phenyl or naphthyl, n - a number 1 or 2, W - a group of the formula R.<sup>7</sup>-CO-, R<sup>8</sup>-SO<sub>2</sub>- or<chemistry id="chem0021" num="0021"><img file="EP0441192A2_D0021.tif" /></chemistry>means, where R<sup>7</sup> and R<sup>8</sup> are identical or different and represent straight-chain or branched alkyl having up to 4 carbon atoms or morpholino, R<sup>9</sup> and R<sup>G</sup>are the same or different and are hydroxyl or alkoxy having up to 4 carbon atoms, R<sup>4 -</sup> a remainder of the formula<chemistry id="chem0022" num="0022"><img file="EP0441192A2_D0022.tif" /></chemistry>means in which the OH functions are optionally protected by acetyl Q means oxygen or sulfur,</li><li>R<sup>5</sup> and R<sup>6</sup> are identical or different and denote hydrogen, straight-chain or branched alkyl having up to 4 carbon atoms or an amino protecting group,</li><li>T - the rest of the formula<chemistry id="chem0023" num="0023"><img file="EP0441192A2_D0023.tif" /></chemistry>means</li><li>A, B and D are the same or different and</li><li>- for a direct bond or</li><li>- stand for proline, or</li><li>- for a group of the formula<chemistry id="chem0024" num="0024"><img file="EP0441192A2_D0024.tif" /></chemistry>stand in what</li><li>R<sup>10</sup> Means hydrogen or methyl,</li><li>R<sup>11</sup> and R<sup>12</sup> are identical or different and mean cyclopentyl or straight-chain or branched alkyl having up to 4 carbon atoms, which is optionally substituted by naphthyl or phenyl, which in turn can be substituted by fluorine, chlorine or alkoxy having up to 4 carbon atoms, or</li><li>Alkyl is substituted by imidazolyl, triazolyl, pyridyl or pyrazolyl, the -NH functions optionally being protected by methyl, Boc or BOM,</li><li>L and M are the same or different and</li><li>- for a direct bond or</li><li>- for a group of the formula<chemistry id="chem0025" num="0025"><img file="EP0441192A2_D0025.tif" /></chemistry>stand in what</li><li>R<sup>10'</sup>, R<sup>11'</sup> and R<sup>12'</sup> the meaning of R given above<sup>10</sup>, R<sup>11</sup> and R<sup>12</sup> have and are the same or different with it,</li><li>in their D or L form, or as a D, L isomer mixture,</li><li>R<sup>1</sup> and R<sup>2</sup> are the same or different and</li><li>stand for straight-chain or branched alkyl having up to 4 carbon atoms, which is optionally substituted by cyclohexyl or phenyl,</li><li>Y - for a group of the formula<chemistry id="chem0026" num="0026"><img file="EP0441192A2_D0026.tif" /></chemistry>or -CO-R<sup>14</sup> stands,</li><li>wherein</li><li>Q and R<sup>4</sup> have the meaning given above,</li><li>R<sup>14</sup> straight-chain or branched alkyl having up to 4 carbon atoms, optionally by pyridyl, phenyl or by the group -NR<sup>15</sup>R<sup>16</sup> is substituted,</li><li>wherein</li><li>R<sup>15</sup> Means hydrogen and</li><li>R<sup>16</sup> a group of the formula<chemistry id="chem0027" num="0027"><img file="EP0441192A2_D0027.tif" /></chemistry>or<chemistry id="chem0028" num="0028"><img file="EP0441192A2_D0028.tif" /></chemistry>means, where W, Q, n, R<sup>3</sup> and R<sup>4</sup> have the meaning given above</li><li>and their physiologically acceptable salts, with the proviso that X may only mean tert-butoxy if Y is for the group<chemistry id="chem0029" num="0029"><img file="EP0441192A2_D0029.tif" /></chemistry>stands.</li><li>In addition, a process for the preparation of the compounds of the general formula (I) according to the invention<chemistry id="chem0030" num="0030"><img file="EP0441192A2_D0030.tif" /></chemistry>in which<ul id="ul0009" list-style="none"><li>X, A, B, D, R<sup>1</sup>, R<sup>2</sup>, L, M, Q and Y have the meaning given above, found, characterized in that</li><li>Compounds of the general formula (II)<chemistry id="chem0031" num="0031"><img file="EP0441192A2_D0031.tif" /></chemistry>in which</li><li>R<sup>1</sup> and R<sup>2</sup> have the meaning given above,</li><li>G - represents one of the amino protecting groups listed above,</li><li>and</li><li>V - represents a residue which can be split off by hydrogenolysis, such as benzyl,</li></ul>first by hydrogenolysis with opening of the isoxazolidine ring to the amino alcohols of the general formula (111)<chemistry id="chem0032" num="0032"><img file="EP0441192A2_D0032.tif" /></chemistry>where G, R<sup>1</sup> and R<sup>2 </sup>have the meaning given above, reduced, if appropriate subsequently with compounds of the general formula (IV) or (IVa)<chemistry id="chem0033" num="0033"><img file="EP0441192A2_D0033.tif" /></chemistry>in which Y has the meaning given above and<ul id="ul0010" list-style="none"><li>L 'and M' have the meaning of L and M given above, but do not simultaneously stand for a direct bond,</li><li>condensed in inert solvents, optionally in the presence of a dehydrating auxiliary and / or a base,</li><li>then after splitting off the protective group G by known method with compounds of the general formula (V)<chemistry id="chem0034" num="0034"><img file="EP0441192A2_D0034.tif" /></chemistry>in which</li><li>B 'and D' have the meaning of B and D given above, but do not simultaneously stand for a direct bond</li><li>and</li><li>G 'has the meaning of G given above and is the same or different with it,</li><li>implemented and in a last step after splitting off the protective group G 'with compounds of the formula (VI)<chemistry id="chem0035" num="0035"><img file="EP0441192A2_D0035.tif" /></chemistry>in which</li><li>X and Q have the meaning given above</li><li>and</li><li>A 'has the meaning of A given above, but does not stand for a direct bond, if appropriate in the presence of a base.</li></ul></li></ul>
0019The method according to the invention can be illustrated by the following formula scheme:<chemistry id="chem0036" num="0036"><img file="EP0441192A2_D0036.tif" /></chemistry><chemistry id="chem0037" num="0037"><img file="EP0441192A2_D0037.tif" /></chemistry>
0020The usual inert solvents which do not change under the reaction conditions are suitable as solvents for all process steps. These preferably include organic solvents such as methanol, ethanol, propanol, isopropanol or ethers such as diethyl ether, glycol mono- or dimethyl ether, dioxane or tetrahydrofuran, or carbons such as benzene, toluene, xylene, cyclohexane or petroleum fractions or halogenated hydrocarbons such as methylene chloride, chloroform, carbon tetrachloride, or acetone , Dimethyl sulfoxide, dimethylformamide, hexamethylphosphoric triamide, ethyl acetate, pyridine, triethylamine or picoline. It is also possible to use mixtures of the solvents mentioned. Methanol and ethyl acetate are particularly preferred for the reduction, methylene chloride for the peptide coupling and reaction with compounds of the general formulas (IV), (IVa) and (VI).
0021The reduction of the compounds of the general formula (II) is carried out either with the customary catalysts, such as, for example, palladium hydroxide or palladium / carbon, preferably with palladium / carbon, or via a catalytic transfer hydrogenation in a manner known per se [cf. Tetrahedron 41, 3469 (1985), 3463 (1985), Synthesis 1987, 531.
0022The catalyst is used in an amount of 0.05 to 1.0 mol, preferably 0.1 to 0.5 mol, based on 1 mol of the compound of the general formula (II).
0023The reduction is carried out in a temperature range from 40 ° C. to 160 ° C., preferably from 60 ° C. to 80 ° C.
0024The reduction can be carried out both at normal pressure and at elevated or reduced pressure (for example 0.5 to 5 bar), preferably at normal pressure.
0025The compounds of general formula (II) are new and can be prepared by using compounds of general formula (VII)<chemistry id="chem0038" num="0038"><img file="EP0441192A2_D0038.tif" /></chemistry>in which<ul id="ul0011" list-style="none"><li>G has the meaning given above,</li><li>in a cycloaddition reaction with compounds of the general formula (VIII)<chemistry id="chem0039" num="0039"><img file="EP0441192A2_D0039.tif" /></chemistry>in which</li><li>V and R<sup>2</sup> have the meaning given above,</li><li>if appropriate in the presence of inert organic solvents.</li></ul>
0026Suitable solvents are the customary organic solvents which do not change under the reaction conditions. These preferably include alcohols such as methanol, ethanol, propanol, isopropanol, n-butanol or ethers such as diethyl ether, dioxane, tetrahydrofuran, glycol mono- or diethyl ether or hydrocarbons such as benzene, toluene, xylene or petroleum fractions or n-butyl acetate. Preferred are n-butanol, dioxane, n-butyl acetate, toluene, xylene or mesitylene.
0027The reaction can be carried out in a temperature range from 0 ° C. to 250 ° C., preferably at 100 ° C. to 170 ° C. under normal or elevated pressure.
0028The compounds of the general formula (VII) are known per se or can be prepared by a customary method [Chem. Pharm. Bull. 30, 1921 (1982), Chem. Pharm. Bull 23, 3106 (1975; J. Org 'Chem. 47, 3016 (1982)).
0029The compounds of the general formula (VIII) are known per se or can be prepared by customary methods [JJ Tufariello in 1,3-Dipolar Cycloaddition Chemistry Vol. 2, Ed. A. Padwa, p-83-168, John Wiley (1984), R. Huisgen, H. Seidel, J. Bruning, Chem. Ber. 102: 1102 (1969)].
0030Some of the compounds of the general formula (III) are known [(R<sup>1</sup> = Butyl, R<sup>2</sup> = Propyl (I)) cf. PCT, WO 88/02374] and can, however, be obtained in the preferred stereochemistry and in better yields by the new process indicated above via the stage of the isoxazolidines (formula II).
0031The compounds of the general formulas (IV) and (V) are known per se and can be reacted by reacting a corresponding fragment, consisting of one or more amino acid units, with a free, optionally in activated form, carboxyl group with a complementary fragment consisting of or several amino acid units, with one amino group, optionally in activated form, and by repeating this process with appropriate fragments, then protective groups can be split off or exchanged for other protective groups [cf. Houben-Weyl, Methods of Organic Chemistry, Synthesis of Peptides II, 4th Edition Vol. 15/1, 15/2, Georg Thieme Verlag, Stuttgart].
0032Condensation agents, which can also be bases, are preferably used as auxiliaries for the peptide coupling and the introduction of the radical Y (formulas (IV) and (IVa)), in particular if the carboxyl group is present as an anhydride. The usual condensing agents such as carbodiimides are preferred here, for example N, N'-diethyl, N, N-'dipropyl, N, N'-diisopropyl, N, N'-dicyclohexylcarbodiimide, N- (3-dimethylamino-isopropyl) -N'-ethylcarbodiimide hydrochloride, or carbonyl compounds such as carbonyldiimidazole, or isoxazolium compounds such as 2-ethyl-5-phenyl-isoxazolium-3-sulfonate or 2-tert-butyl-5-methyl-isoxazolium perchlorate, or acylamino compounds such as 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline , or propanephosphonic anhydride, or isobutyl chloroformate, or benzotriazolyloxy tris (dimethylamino) phosphonium hexafluorophosphate.
0033Bases which can be used in the peptide coupling and in the reaction with compounds of the general formula (VI) are alkali carbonate, for example sodium or potassium carbonate or hydrogen carbonate, or organic bases such as trialkylamine, for example triethylamine, N-ethylmorpholine, N-methylpiperidine or N-methylmorpholine. Triethylamine is preferred.
0034The auxiliaries and bases are used in an amount of 0.5 mol to 4 mol, preferably 1 to 1.5 mol, based on 1 mol of the compounds of the general formula (VI).
0035The peptide coupling is carried out in a temperature range from -20 ° C to 100 ° C, preferably at 0 to 25 C and at normal pressure.
0036The radicals X and Y are introduced in a temperature range from 0 ° C. to + 90 ° C., preferably at room temperature.
0037The reactions can be carried out both at normal pressure and at elevated or reduced pressure (for example 0.5 to 5 bar), preferably at normal pressure.
0038The compounds of the general formulas (IVa) and (VI) are known per se or can be prepared by a customary method.
0039The respective protective groups are split off before the individual peptide linkages in a manner known per se under acidic or basic conditions, or reductively by catalytic hydrogenation, for example with Pd / C, in organic solvents such as ethers, for example tetrahydrofuran or dioxane, or alcohols, for example methanol, ethanol or isopropanol [see. Protective Groups in Organic Synthesis, W. Greene, John Wiley & Sons, New York, 1981; Chemistry and Biochemistry of the Amino Acids, GC Barrett, Chapman and Hall, London, New York, 1985].
In vitro test
0040The inhibitory strength of the peptides according to the invention against endogenous renin from human plasma is determined in vitro. Pooled human plasma is obtained with the addition of ethylenediaminetetraacetic acid (EDTA) as an anticoagulant and stored at -20 ° C. Plasma renin activity (PRA) is determined as the rate of formation of angiotensin I from endogenous angiotensinogen and renin after incubation at 37 ° C. The reaction solution contains 150 ul plasma, 3 ul 6.6% 8-hydroxyquinoline sulfate solution, 3 ul 10% dimercaprol solution and 144 ul sodium phosphate buffer (0.2 M; 0.1% EDTA; pH 5.6) with or without the invention Substances in different concentrations. The angiotensin I formed per unit of time is determined using a radioimmunoassay (Sorin Biomedica, Italy). The percentage inhibition of plasma renin activity is calculated by comparing the substances claimed here. The concentration range in which the substances claimed here show a 50% inhibition of plasma arena activity is between 10-<sup>4</sup> and 10-<sup>9</sup> M.
0041The standard concentration of the following renin inhibitors used is 50 gg / ml. If the inhibition was more than 90%, the IC 50 values were determined.<tables id="tabl0001" num="0001"><img file="EP0441192A2_D0040.tif" /></tables>
0042The new active compounds can be converted in a known manner into the customary formulations, such as tablets, dragees, pills, granules, aerosols, syrups, emulsions, suspensions and solutions, using inert, non-toxic, pharmaceutically suitable excipients or solvents. The therapeutically active compound should in each case be present in a concentration of about 0.5 to 90% by weight of the total mixture, ie in amounts sufficient to achieve the dosage range indicated.
0043The formulations are prepared, for example, by stretching the active ingredients with solvents and / or carriers, if appropriate using emulsifiers and / or dispersants, it being possible, for example if organic solvents to be used as diluents, to use organic solvents as auxiliary solvents.
0044Examples of auxiliary substances are:<ul id="ul0012" list-style="none"><li>Water, non-toxic organic solvents, such as paraffins (e.g. petroleum fractions), vegetable oils (e.g. peanut / sesame oil), alcohols (e.g.: ethyl alcohol, glycerin), carriers, such as natural rock flour (e.g. kaolins, clays, talc, chalk), synthetic rock flour (e.g. highly disperse silica, silicates), sugar (e.g. cane, milk and dextrose), emulsifiers (e.g. polyoxyethylene fatty acid ester), polyoxyethylene fatty alcohol ether (e.g. Lignin, sulfite liquor, methyl cellulose, starch and polyvinyl pyrrolidone) and lubricants (e.g. magnesium stearate, talc, stearic acid and sodium lauryl sulfate).</li></ul>
0045The application is carried out in the usual way, preferably orally or parenterally, in particular perlingually or intravenously. In the case of oral use, tablets can of course also contain additives, such as sodium citrate, calcium carbonate and dicalcium phosphate, together with various additives, such as starch, preferably potato starch, gelatin and the like, in addition to the carrier substances mentioned. Lubricants such as magnesium stearate, sodium lauryl sulfate and talc can also be used for tableting. In the case of aqueous suspensions, in addition to the auxiliaries mentioned above, the active ingredients can be mixed with various flavor enhancers or colorants.
0046In the case of parenteral use, solutions of the active ingredients can be used using suitable liquid carrier materials.
0047In general, it has proven to be advantageous to administer amounts of approximately 0.001 to 1 mg / kg, preferably approximately 0.01 to 0.5 mg / kg of body weight in the case of intravenous administration, in order to achieve effective results, and the dosage is approximately in the case of oral administration 0.01 to 20 mg / kg, preferably 0.1 to 10 mg / kg body weight.
0048Nevertheless, it may be necessary to deviate from the quantities mentioned, depending on the body weight of the test animal or the type of application, but also on the basis of the animal type and its individual behavior towards the medication or its type, its formulation and the time or interval at which the administration takes place.
0049In some cases it may be sufficient to make do with less than the above-mentioned minimum quantity, while in other cases the above-mentioned upper limit must be exceeded. In the case of application of larger quantities, it may be advisable to distribute them in several single doses throughout the day. The same dosage range is provided for application in human medicine. The above statements also apply mutatis mutandis.
Attachment 1
1. amino acids
0050In general, the name of the configuration is given by prefixing an L or D before the amino acid abbreviation, in the case of the racemate by a D, L-, for simplification the configuration name can be omitted for L-amino acids and then only in the case of the D form or the D, L mixture is explicitly named.
a) natural amino acids
0051<ul id="ul0013" list-style="none"><li>Ala L-Alanine</li><li>Asp L-Aspartic Acid</li><li>Cys L-cysteine</li><li>Oln L-glutamine</li><li>Glu L-glutamic acid</li><li>Gly L-glycine</li><li>His L-histidine</li><li>Ile L-isoleucine</li><li>Leu L-leucine</li><li>Lys L-lysine</li><li>Phe phenylalanine</li><li>Cpg cyclopentylglycine</li><li>Val valine</li></ul>
2nd Activation reagents and additives
0052<ul id="ul0014" list-style="none"><li>HOBT 1-hydroxybenzotriazole</li><li>HOSU N-hydroxysuccinimide</li><li>DCC dicyclohexylcarbodiimide</li><li>NMM N-methylmorpholine</li><li>BOP benzotriazolyloxy tris (dimethylamino) phosphonium hexafluorophosphate</li></ul>
3rd Protecting groups
0053<ul id="ul0015" list-style="none"><li>BOC tert-butoxycarbonyl</li><li>Z benzyloxycarbonyl</li><li>AMP 2-aminomethylpyridyl</li><li>BOM benzyloxymethyl</li><li>PAA pyridylacetyl</li></ul>
Appendix 11
0054The following eluent systems were used:<tables id="tabl0002" num="0002"><img file="EP0441192A2_D0041.tif" /></tables>
0055For the connections marked with x, lie <sup>1</sup>H NMR data available.
0056The radical t listed in the examples stands for the tert-butyl group.
Output connections
example 1
BOC-phenylalanine
0057<chemistry id="chem0040" num="0040"><img file="EP0441192A2_D0042.tif" /></chemistry>
0058300 g (1.91 mol) of L-phenylalanine are dissolved in 360 ml of dioxane and 360 ml of H<sub>2</sub>O suspended. 432.9 g (1.98 mol) of di-tert-butyl dicarbonate are added with stirring at pH 9.8. The pH is kept constant with about 975 ml of 4N NaOH. After 16 h the reaction mixture is extracted with ether, the aqueous phase is adjusted to pH 3-4 with citric acid and then extracted with 2 x ether, 2 x ethyl acetate. The organic phases are combined and washed 3 times with water. After spinning in and crystallization from diethyl ether / hexane, 291.6 g (60.7%) are obtained.
0059Mp: 88-89C
0060NMR (DMSO, 300 MHz): 8 = 1.35 (s; 9H, C (CH<sub>3</sub>)<sub>3</sub>).
Example 11
BOC cyclohexylalanine
0061<chemistry id="chem0041" num="0041"><img file="EP0441192A2_D0043.tif" /></chemistry>
0062265 g (1.0 mol) of the compound from Example I are dissolved in 2 I of methanol and hydrogenated over 20 g of 5% Rh / C at 40 atm for 5 h. The catalyst is filtered off with Celite, washed with methanol and the solution obtained is concentrated. 271 g (100%) of Example 6 are obtained.
0063NMR (DMSO, 300 MHz): δ = 0.8-1.8 (m; 22H, cyclohexylmethylene, C (CH<sub>3</sub>)<sub>3</sub>.
Example III
BOC-cyclohexylalanine-N-methyl-N-methoxyamide
0064<chemistry id="chem0042" num="0042"><img file="EP0441192A2_D0044.tif" /></chemistry>
0065163.0 g (0.601 mol) of the compound from Example II and 40.3 g (0.661 mol) of N, O-dimethylhydroxylamine are dissolved in 2 l of methylene chloride at room temperature. 303.5 g (3.005 mol) of triethylamine (pH-8) are added dropwise at 0.degree. At max. -10 ° C 390.65 ml of a 50% solution (0.601 mol) of n-propylphosphonic anhydride in methylene chloride is added dropwise. The mixture is warmed to 25 ° C. overnight and stirred for 16 hours. The reaction solution is then concentrated, the residue is saturated with 500 ml. Bicarbonate solution added and 20 min, at 25<sup>0</sup> C stirred. After extraction three times with ethyl acetate, the organic phase is washed over Na<sub>2</sub>SO<sub>4</sub> dried and concentrated. Crude yield: 178 g (94.6%). The raw material is chromatographed on silica gel (mobile phase F).
0066Yield: 136.6 9 (72.3%).
0067NMR (DMSO, 300 MHz): δ = 1.37 (s; 9H, C (CH<sub>3</sub>)<sub>3</sub>), 3.08 (s; 3H, N-CH<sub>3</sub>); 3.71 (s; 3H; O-CH<sub>3</sub>).
Example IV
BOC-cyclohexylalaninal
0068<chemistry id="chem0043" num="0043"><img file="EP0441192A2_D0045.tif" /></chemistry>
006963.7 g (0.21 mol) of the compound from Example III are dissolved in 1.5 l of anodized ether in a heated apparatus under nitrogen, at 0 ° C. 10 g (0.263 mol) of LiAlH<sub>4</sub> added in portions, and then 20 min. stirred at 0 ° C. Then a solution of 50 g (0.367 mol) of KHS0 is carefully added<sub>4</sub> in 1 IH<sub>2</sub>O added dropwise at 0 ° C. The phases are separated, the aqueous phase extracted 3 times with 300 ml of diethyl ether, the combined organic phases three times with 3N HCl, 3 times with NaHCO<sub>3</sub>Solution and washed twice with NaCl solution. The organic phase is over Na<sub>2</sub>S0<sub>4</sub> dried and concentrated. Yield: 45 g (84.1%). The aldehyde is either processed immediately or stored at -24 ° C for one to two days.
0070NMR (DMSO, 300 MHz): δ = 9.41 (s; 1 H, -CHO).
Example V
BOC allylamine
0071<chemistry id="chem0044" num="0044"><img file="EP0441192A2_D0046.tif" /></chemistry>
007214.6 9 (35 mmol) "Instant Ylide" (Fluka 69500) are suspended in 90 ml of anhydrous tetrahydrofuran. A solution of 9.0 g (35 mmol) of BOC-cyclohexylalaninal in 45 ml of anhydrous tetrahydrofuran is added dropwise with ice cooling at a reaction temperature between 20 and 25 ° C. After 15 min. While stirring, the reaction mixture is poured onto 250 ml of ice and extracted twice with 150 ml of ethyl acetate / n-hexane 3: 1. After drying over NazS04 and concentration, the residue is chromatographed on silica gel (mobile phase D).
0073Yield: 3.2 g (40.0%)
0074EI-MS: m / z = 253 (0.1% M + H), 197 (9%).
Example VI
BOC allylamine
0075<chemistry id="chem0045" num="0045"><img file="EP0441192A2_D0047.tif" /></chemistry>
0076Representation is carried out analogously to the procedure from Example V with a 0.24 mol batch. Yield: 25.92 g (50.6%).
Example VII
2-Benzyl-3 (1-methylethyl) -5- [1-tert-butoxycarbonylamino-2-cyclohexylethyl] isoxazolidine
0077<chemistry id="chem0046" num="0046"><img file="EP0441192A2_D0048.tif" /></chemistry>
0078202.4 9 (0.8 mol) of the compound from Example V are dissolved in 1000 ml of mesitylene and heated to 140 ° C. on a water separator. At this temperature, a mixture of 197 g (1.6 mol) of N-benzylhydroxylamine and 137.68 g (1.6 mol) of isobutyraldehyde in 800 ml of mesitylene is added dropwise over 2 hours. After 4h and 8h reaction time, the same amount of N-benzylhydroxylamine, isobutyraldehyde in mesitylene is added dropwise. After a total of 16h reaction time, the mixture is concentrated, the residue is mixed with diethyl ether and then with 1m KHSO<sub>4</sub>Solution washed. After drying over Na<sub>2</sub>S0<sub>4</sub> and the mixture was chromatographed on silica gel (mobile phase B).
0079Yield: 168 g (52.2% of theory)
00804 diastereomers were obtained:<tables id="tabl0003" num="0003"><img file="EP0441192A2_D0049.tif" /></tables>
0081The examples listed in Table I were prepared in analogy to the procedure of Example VII:<tables id="tabl0004" num="0004"><img file="EP0441192A2_D0050.tif" /></tables>
Example X
(2R, 4S, 5S) -2-amino-5- (tert.butoxycarbonylamino) -6-cyclohexyl-4-hydroxyhexane
0082<chemistry id="chem0047" num="0047"><img file="EP0441192A2_D0051.tif" /></chemistry>
008318.1 g (45 mmol) of the compound from Example IX (diastereomer C) are dissolved in 300 ml of methanol. After the addition of 14.2 9 (225 mmol) ammonium formate is intensively with N<sub>2</sub> rinsed and 3.6 g palladium / carbon (10%) added. The mixture is stirred under reflux for 3 h. After cooling, the catalyst is filtered off, the solution is concentrated, dissolved in ethyl acetate and washed twice with saturated bicarbonate solution. The organic phase is dried over sodium sulfate, filtered, concentrated and dried in a high vacuum. Yield: 11.36 g (80.3% of theory)<maths id="math0001" num=""><img file="EP0441192A2_D0052.tif" /></maths>
0084The compounds listed in Table II were prepared in analogy to the procedure of Example X.<tables id="tabl0005" num="0005"><img file="EP0441192A2_D0053.tif" /></tables>
Example XIII
(2R, 4S, 5S) -2- (valerylamino) -5- (tert.butoxycarbonylamino) -6-cyclohexyl-4-hydroxyhexane
0085<chemistry id="chem0048" num="0048"><img file="EP0441192A2_D0054.tif" /></chemistry>
00866.6 g (21 mmol) of the compound from Example X are dissolved in 500 ml of methylene chloride. Excluding moisture (CaCl<sub>2</sub>Tube), a solution of pentanoic anhydride [prepared from 2.16 g (21 mmol) of pentanoic acid and 2.16 g (10.5 mmol) of dicyclohexylcarbodiimide in 50 ml of methylene chloride, filtration] in methylene chloride is added at room temperature. After 3 h, the mixture is concentrated, taken up in ethyl acetate, washed with saturated bicarbonate solution and dried over sodium sulfate. After filtration and concentration, it is dried under high vacuum.
0087Yield: 8.0 g (95.2% of theory)<maths id="math0002" num=""><img file="EP0441192A2_D0055.tif" /></maths>FAB-MS: m / z = 421 (12%, M + Na)
0088The compounds listed in Table III were prepared in analogy to the procedure of Example XIII.<tables id="tabl0006" num="0006"><img file="EP0441192A2_D0056.tif" /></tables>
Example XVI
(2R, 4S, 5S) -2- (valerylamino) -5- [Nα- (tert.butoxycarbonyl) -Nπ- (tert.butoxycarbonyl) -L-histidylamino] -6-cyclohexyl-4-hydroxyhexane
0089<chemistry id="chem0049" num="0049"><img file="EP0441192A2_D0057.tif" /></chemistry>
00907.57 g (19 mmol) of the compound from Example XIII are stirred in 70 ml of 4N hydrochloric acid / dioxane for 30 minutes with the exclusion of moisture. The solution is concentrated, diethyl ether is added and the mixture is evaporated to dryness. After drying under high vacuum, 5.54 g (16.5 mmol) of the corresponding hydrochloride, 4.46 g (33 mmol) of HOBT and 5.86 g (16.5 mmol) of Boc-His (Boc) OH in 500 ml of methylene chloride solved. After cooling to 0 ° C., the pH is adjusted to 8.5 with N-methylmorpholine and 3.57 g (17.3 mmol) of dicyclohexylcarbodiimide are added. After 16 h at 20 ° C., the urea is filtered off, the solution is concentrated, taken up in ethyl acetate and washed with saturated bicarbonate solution. After drying over sodium sulfate, the mixture is concentrated and dried in a high vacuum.
0091Yield: 8.33 g (79.5% of theory)<maths id="math0003" num=""><img file="EP0441192A2_D0058.tif" /></maths>FAB-MS: m / z = 636 (79%, M + H)
0092The examples listed in Table IV were prepared in analogy to the procedure of Example XVI.<tables id="tabl0007" num="0007"><img file="EP0441192A2_D0059.tif" /></tables>
Example XIX
(2R, 4S, 5S) -2- (valerylamino) -5- [Nα- (tert.butoxycarbonyl) -L-cyclopentylglycylamino] -6-cyclohexyl-4-hydroxylhexane
0093<chemistry id="chem0050" num="0050"><img file="EP0441192A2_D0060.tif" /></chemistry>
00945.6 g (24.4 mmol) of BocCpgOH are dissolved in 50 ml of anhydrous tetrahydrofuran. After adding 2.7 ml (24.4 mmol) of N-methylmorpholine, 3.2 ml (24.4 mmol) of isobutyl chloroformate is added dropwise at -20 ° C. and the mixture is stirred for 15 min. stirred at -20 ° C. 5.45 g (16.3 mmol) of the deblocked compound from Example XIII and 1.8 ml (16.3 mmol) of the N-methylmorpholine in 50 ml of tetrahydrofuran / water are added dropwise to this solution 1: 1 and within 30 min warmed to 20 ° C. After a further 30 min the reaction solution is concentrated, placed in 1 l of diethyl ether and cooled to 0 ° C. After 16 h, 4.6 g (54.0%) of crystals are filtered off with suction. The mother liquor is washed with saturated bicarbonate solution, the ether phase is dried over sodium sulfate, concentrated and dried in a high vacuum. 6 g of yellow oil are obtained, which is chromatographed on silica gel (E). Yield: 3.31 g (38.8% of theory)<maths id="math0004" num=""><img file="EP0441192A2_D0061.tif" /></maths>
0095FAB-MS: m / z = 524 (38%, M + H)
Manufacturing examples
example 1
(2R, 4S, 5S) -2- (valerylamino) -5- [Nα- (2-S-benzyl-3-tert-butylsulfonylpropionyl) -L-histidylamino] -6-cyclohexyl-4-hydroxyhexane
0096<chemistry id="chem0051" num="0051"><img file="EP0441192A2_D0062.tif" /></chemistry>
00971.145 g (1.8 mmol) of the compound from Example XVI are stirred in 11 ml of 4N hydrochloric acid / dioxane for 30 minutes. The solution is concentrated, diethyl ether is added and the mixture is evaporated to dryness. After drying under high vacuum, 875.5 mg (1.8 mmol) of the resulting dihydrochloride are dissolved in 50 ml of methylene chloride and cooled to 0 ° C. After adding 509.4 mg (1.8 mmol) of the β-tert-butylsulfonyl-a-benzylpropionic acid, the pH is adjusted to 8 with triethylamine and 875.2 mg (1.98 mmol) of BOP are added. After 16 h reaction at room temperature, the mixture is concentrated, taken up in ethyl acetate and washed 3 times with saturated bicarbonate solution. 494.8 mg (39.2% of theory) are obtained, which are chromatographed on silica gel (G).<maths id="math0005" num=""><img file="EP0441192A2_D0063.tif" /></maths>FAB-MS: m / z = 702 (100%, M + H)
Example 2
(2R, 4S, 5S) -2- (valerylamino) -5- {Nα- [4- (morpholinocarbonyl) -L-phenylalanyl] -L-cyclopentylglycylamino} -6-cyclohexyl-4-hydroxyhexane
0098<chemistry id="chem0052" num="0052"><img file="EP0441192A2_D0064.tif" /></chemistry>
00991.044 g (3.75 mmol) of morpholinocarbonylphenylalanine are dissolved in 50 ml of anhydrous tetrahydrofuran. After adding 0.4 ml (3.75 mmol) of N-methylmorpholine, 0.48 ml (3.75 mmol) of isobutyl chloroformate is added dropwise at -20 ° C. and the mixture is stirred at -20 ° C. for 15 min. In this solution, 1.17 g (2.5 mmol) of the deblocked compound from Example XIX in 50 ml of tetrahydrofuran / water 1: 1 [adjusted to pH 8 with N-methylmorpholine] is added dropwise and the mixture is heated to 20 ° C. for 16 h. The processing is carried out as described in Example XIX.
0100Crystals: 944.5 mg (55.5% of theory)
0101Oil 800 mg: after column chromatography 108.2 mg (6.4% of theory)
0102Overall yield: 1.053 g (64.9% of theory)<maths id="math0006" num=""><img file="EP0441192A2_D0065.tif" /></maths>FAB-MS: m / z = 624 (100% M + H)
0103The examples listed in Table 1 were prepared in analogy to the procedure of Example 1:<tables id="tabl0008" num="0008"><img file="EP0441192A2_D0066.tif" /></tables><tables id="tabl0009" num="0009"><img file="EP0441192A2_D0067.tif" /></tables><tables id="tabl0010" num="0010"><img file="EP0441192A2_D0068.tif" /></tables><tables id="tabl0011" num="0011"><img file="EP0441192A2_D0069.tif" /></tables>
0104The compounds listed in Table 2 were prepared in analogy to the procedure of Example 2:<tables id="tabl0012" num="0012"><img file="EP0441192A2_D0070.tif" /></tables><tables id="tabl0013" num="0013"><img file="EP0441192A2_D0071.tif" /></tables><tables id="tabl0014" num="0014"><img file="EP0441192A2_D0072.tif" /></tables><tables id="tabl0015" num="0015"><img file="EP0441192A2_D0073.tif" /></tables><tables id="tabl0016" num="0016"><img file="EP0441192A2_D0074.tif" /></tables><tables id="tabl0017" num="0017"><img file="EP0441192A2_D0075.tif" /></tables>
134 sheets
Sheet 1 Sheet 2 Sheet 3 Sheet 4 Sheet 5 Sheet 6 Sheet 7 Sheet 8 Sheet 9 Sheet 10 Sheet 11 Sheet 12 Sheet 13 Sheet 14 Sheet 15 Sheet 16 Sheet 17 Sheet 18 Sheet 19 Sheet 20 Sheet 21 Sheet 22 Sheet 23 Sheet 24 Sheet 25 Sheet 26 Sheet 27 Sheet 28 Sheet 29 Sheet 30 Sheet 31 Sheet 32 Sheet 33 Sheet 34 Sheet 35 Sheet 36 Sheet 37 Sheet 38 Sheet 39 Sheet 40 Sheet 41 Sheet 42 Sheet 43 Sheet 44 Sheet 45 Sheet 46 Sheet 47 Sheet 48 Sheet 49 Sheet 50 Sheet 51 Sheet 52 Sheet 53 Sheet 54 Sheet 55 Sheet 56 Sheet 57 Sheet 58 Sheet 59 Sheet 60 Sheet 61 Sheet 62 Sheet 63 Sheet 64 Sheet 65 Sheet 66 Sheet 67 Sheet 68 Sheet 69 Sheet 70 Sheet 71 Sheet 72 Sheet 73 Sheet 74 Sheet 75 Sheet 76 Sheet 77 Sheet 78 Sheet 79 Sheet 80 Sheet 81 Sheet 82 Sheet 83 Sheet 84 Sheet 85 Sheet 86 Sheet 87 Sheet 88 Sheet 89 Sheet 90 Sheet 91 Sheet 92 Sheet 93 Sheet 94 Sheet 95 Sheet 96 Sheet 97 Sheet 98 Sheet 99 Sheet 100 Sheet 101 Sheet 102 Sheet 103 Sheet 104 Sheet 105 Sheet 106 Sheet 107 Sheet 108 Sheet 109 Sheet 110 Sheet 111 Sheet 112 Sheet 113 Sheet 114 Sheet 115 Sheet 116 Sheet 117 Sheet 118 Sheet 119 Sheet 120 Sheet 121 Sheet 122 Sheet 123 Sheet 124 Sheet 125 Sheet 126 Sheet 127 Sheet 128 Sheet 129 Sheet 130 Sheet 131 Sheet 132 Sheet 133 Sheet 134
Every citation, both ways
| Document | Relation | Office | Category | Cited during |
|---|---|---|---|---|
| WO2009040363A1 | Cited by | World Intellectual Property Organization (WIPO) | – | Applicant |
| US5583233A | Cited by | United States of America | – | Search report |
| CN1313472C | Cited by | China | – | Search report |
| US5552558A | Cited by | United States of America | – | Search report |
| WO2009040363A1 | Cited by | World Intellectual Property Organization (WIPO) | – | International search |
| US7427624B2 | Cited by | United States of America | – | Applicant |
| WO9314096A1 | Cited by | World Intellectual Property Organization (WIPO) | – | International search |
| US5597928A | Cited by | United States of America | – | Search report |
| US5541334A | Cited by | United States of America | – | Search report |
| WO03090690A3 | Cited by | World Intellectual Property Organization (WIPO) | – | International search |
| US6667404B2 | Cited by | United States of America | – | Applicant |
| US6150530A | Cited by | United States of America | – | Search report |
| US6017928A | Cited by | United States of America | – | Search report |
| US5616714A | Cited by | United States of America | – | Search report |
| US9783568B2 | Cited by | United States of America | – | Applicant |
| WO03090690A2 | Cited by | World Intellectual Property Organization (WIPO) | – | International search |
| US5354866A | Cited by | United States of America | – | Search report |
| US5583232A | Cited by | United States of America | – | Search report |
| US7273717B2 | Cited by | United States of America | – | Applicant |
| US5565418A | Cited by | United States of America | – | Search report |
| US6531610B1 | Cited by | United States of America | – | Applicant |
| US7645747B2 | Cited by | United States of America | – | Applicant |
| US10851125B2 | Cited by | United States of America | – | Applicant |
| US7432272B2 | Cited by | United States of America | – | Applicant |
| US8022083B2 | Cited by | United States of America | – | Applicant |
| WO03090690A3 | Cited by | World Intellectual Property Organization (WIPO) | – | International search |
| US5886036A | Cited by | United States of America | – | Search report |
| US7432261B2 | Cited by | United States of America | – | Applicant |
| US5696270A | Cited by | United States of America | – | Search report |
| US5597926A | Cited by | United States of America | – | Search report |
| US7649015B2 | Cited by | United States of America | – | Applicant |
| US5541206A | Cited by | United States of America | – | Search report |
| US7417055B2 | Cited by | United States of America | – | Applicant |
| US5608072A | Cited by | United States of America | – | Search report |
| US5846987A | Cited by | United States of America | – | Search report |
| US5837873A | Cited by | United States of America | – | Search report |
| US5679797A | Cited by | United States of America | – | Search report |
| US5554783A | Cited by | United States of America | – | Search report |
| US7407965B2 | Cited by | United States of America | – | Applicant |
| US7427636B2 | Cited by | United States of America | – | Applicant |
| US5539122A | Cited by | United States of America | – | Search report |
| US8785594B2 | Cited by | United States of America | – | Applicant |
| US7273716B2 | Cited by | United States of America | – | Applicant |
| US7432273B2 | Cited by | United States of America | – | Applicant |
| US5659045A | Cited by | United States of America | – | Search report |
| US5892052A | Cited by | United States of America | – | Search report |
| EA008775B1 | Cited by | Eurasian Patent Organization (EAPO) | – | Search report |
| US7470724B2 | Cited by | United States of America | – | Applicant |
| US7300924B2 | Cited by | United States of America | – | Applicant |
| US5597927A | Cited by | United States of America | – | Search report |
| US5625072A | Cited by | United States of America | – | Search report |
| US5648497A | Cited by | United States of America | – | Search report |
| US8658617B2 | Cited by | United States of America | – | Applicant |
| US7273715B2 | Cited by | United States of America | – | Applicant |
| US7429565B2 | Cited by | United States of America | – | Applicant |
| US5616720A | Cited by | United States of America | – | Search report |
| US5659044A | Cited by | United States of America | – | Search report |
| US7462608B2 | Cited by | United States of America | – | Applicant |
| US5591860A | Cited by | United States of America | – | Search report |
| US7452901B2 | Cited by | United States of America | – | Applicant |
| EP0223437A2 | Cites | European Patent Office (EPO) | Y | Search report |
| JOURNAL OF MEDICINAL CHEMISTRY Bd. 30, 1987, WASHINGTON Seiten 1224 - 1228; ROSENBERG ET AL: 'Novel renin inhibitors containing analogues of statine retro-inverted at the C-termini: Specificity at the P2 histidine site' | Non-patent | – | – | Search report |
| CHEMICAL ABSTRACTS, vol. 112, 1990, Columbus, Ohio, US; abstract no. 199134F, RADDATZ ET AL: 'Preparation and formulation of peptide amides and peptide ureas as renin inhibitors' Seite 791 ;Spalte 2 ; | Non-patent | – | – | Search report |
4 priority claims, no other members on record
Priority claims4
| Document | Office | Kind | Date |
|---|---|---|---|
| 4003574 | Germany | A | |
| 4003574 | Germany | – | |
| DE19904003574 | – | – | – |
| 4003574 | – | – | – |
6 legal events, as the office reported them to INPADOC
Over the term
Point at a mark for the eventEvents
| Event | Code | |
|---|---|---|
| Application withdrawnWithdrawn18W | 18W | |
| Designated contracting statesAK | AK | |
| Information on the status of an ep patent application or granted ep patentGrantedSTATUS: THE APPLICATION HAS BEEN WITHDRAWNSTAA | STAA | |
| Search report despatchedORIGINAL CODE: 0009013PUAL | PUAL | |
| Designated contracting statesAK | AK | |
| Public reference made under article 153(3) epc to a published international application that has entered the european phaseORIGINAL CODE: 0009012PUAI | PUAI |
Numbers
- Publication
- 0441192
- Publication, DOCDB
- 0441192
- Publication, EPODOC
- EP0441192
- Application
- 91100932
- Application, DOCDB
- 91100932
- Application, EPODOC
- EP19910100932
Titles6
- German
- Retroisostere Dipeptide, Verfahren zu ihrer Herstellung und ihre Verwendung als Renininhibitoren in Arzneimitteln.
- English
- Retroisosteric dipeptides, their preparation and use as renin inhibitors in pharmaceutical compositions.
- French
- Dipeptides rétroisostériques, leur préparation et leur utilisation comme inhibiteur de rénine dans des compositions pharmaceutiques.
- German
- Retroisostere Dipeptide, Verfahren zu ihrer Herstellung und ihre Verwendung als Renininhibitoren in Arzneimitteln
- English
- Retroisosteric dipeptides, their preparation and use as renin inhibitors in pharmaceutical compositions
- French
- Dipeptides rétroisostériques, leur préparation et leur utilisation comme inhibiteur de rénine dans des compositions pharmaceutiques
Classification
- CPC, 10
- C07D233/64
- A61K38/00
- A61P9/12
- C07C237/22
- C07C271/22
- C07C317/44
- C07C2601/08
- C07C2601/14
- C07D401/12
- C07K5/021
- IPC, 16
- A61K38 55
- A61K38 00
- A61P9 12
- C07C237 22
- C07C271 22
- C07C317 44
- C07D233 54
- C07D233 64
- C07D261 02
- C07D401 12
- C07F9 38
- C07K1 113
- C07K5 02
- C07K5 06
- C07K9 00
- C07K14 81
Designated states14
- Contracting states, 14
- Austria
- Belgium
- Switzerland
- Germany
- Denmark
- Spain
- France
- United Kingdom
- Greece
- Italy
- Liechtenstein
- Luxembourg
- Netherlands (Kingdom of the)
- Sweden